Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors
Neoantigen (neoAg)-based cancer vaccines expand preexisting antitumor immunity and elicit novel cancer-specific T cells. However, at odds with prophylactic vaccines, therapeutic antitumor immunity must be induced when the tumor is present and has already established an immunosuppressive environment...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295032992400002X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846159073352876032 |
|---|---|
| author | Fulvia Troise Guido Leoni Emanuele Sasso Mariarosaria Del Sorbo Marialuisa Esposito Giuseppina Romano Simona Allocca Guendalina Froechlich Gabriella Cotugno Stefania Capone Antonella Folgori Elisa Scarselli Anna Morena D’Alise Alfredo Nicosia |
| author_facet | Fulvia Troise Guido Leoni Emanuele Sasso Mariarosaria Del Sorbo Marialuisa Esposito Giuseppina Romano Simona Allocca Guendalina Froechlich Gabriella Cotugno Stefania Capone Antonella Folgori Elisa Scarselli Anna Morena D’Alise Alfredo Nicosia |
| author_sort | Fulvia Troise |
| collection | DOAJ |
| description | Neoantigen (neoAg)-based cancer vaccines expand preexisting antitumor immunity and elicit novel cancer-specific T cells. However, at odds with prophylactic vaccines, therapeutic antitumor immunity must be induced when the tumor is present and has already established an immunosuppressive environment capable of rapidly impairing the function of anticancer neoAg T cells, thereby leading to lack of efficacy. To overcome tumor-induced immunosuppression, we first vaccinated mice bearing immune checkpoint inhibitor (CPI)-resistant tumors with an adenovirus vector encoding a set of potent cancer-exogenous CD8 and CD4 T cell epitopes (Ad-CAP1), and then “taught” cancer cells to express the same epitopes by using a tumor-retargeted herpesvirus vector (THV-CAP1). Potent CD8 effector T lymphocytes were elicited by Ad-CAP1, and subsequent THV-CAP1 delivery led to a significant delay in tumor growth and even cure. |
| format | Article |
| id | doaj-art-fc4bd76adccd4bc2b29893dea533863b |
| institution | Kabale University |
| issn | 2950-3299 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncology |
| spelling | doaj-art-fc4bd76adccd4bc2b29893dea533863b2024-11-24T04:15:26ZengElsevierMolecular Therapy: Oncology2950-32992024-03-01321200760Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumorsFulvia Troise0Guido Leoni1Emanuele Sasso2Mariarosaria Del Sorbo3Marialuisa Esposito4Giuseppina Romano5Simona Allocca6Guendalina Froechlich7Gabriella Cotugno8Stefania Capone9Antonella Folgori10Elisa Scarselli11Anna Morena D’Alise12Alfredo Nicosia13Nouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyNouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy; CEINGE-Advanced Biotechnologies S.c. a.r.l, Via Gaetano Salvatore 486, 80145 Naples, ItalyReiThera S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyReiThera S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyNouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyNouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyCEINGE-Advanced Biotechnologies S.c. a.r.l, Via Gaetano Salvatore 486, 80145 Naples, ItalyNouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyReiThera S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyReiThera S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyNouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyNouscom S.r.l, Via di Castel Romano 100, 00128 Rome, Italy; Corresponding author: Anna Morena D’Alise, Nouscom S.r.l, Via di Castel Romano 100, 00128 Rome, ItalyDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy; CEINGE-Advanced Biotechnologies S.c. a.r.l, Via Gaetano Salvatore 486, 80145 Naples, ItalyNeoantigen (neoAg)-based cancer vaccines expand preexisting antitumor immunity and elicit novel cancer-specific T cells. However, at odds with prophylactic vaccines, therapeutic antitumor immunity must be induced when the tumor is present and has already established an immunosuppressive environment capable of rapidly impairing the function of anticancer neoAg T cells, thereby leading to lack of efficacy. To overcome tumor-induced immunosuppression, we first vaccinated mice bearing immune checkpoint inhibitor (CPI)-resistant tumors with an adenovirus vector encoding a set of potent cancer-exogenous CD8 and CD4 T cell epitopes (Ad-CAP1), and then “taught” cancer cells to express the same epitopes by using a tumor-retargeted herpesvirus vector (THV-CAP1). Potent CD8 effector T lymphocytes were elicited by Ad-CAP1, and subsequent THV-CAP1 delivery led to a significant delay in tumor growth and even cure.http://www.sciencedirect.com/science/article/pii/S295032992400002XMT: Regular Issuecancer vaccineadenovirus vectorsherpesvirus vectorsimmune checkpoint inhibitorsneoantigens |
| spellingShingle | Fulvia Troise Guido Leoni Emanuele Sasso Mariarosaria Del Sorbo Marialuisa Esposito Giuseppina Romano Simona Allocca Guendalina Froechlich Gabriella Cotugno Stefania Capone Antonella Folgori Elisa Scarselli Anna Morena D’Alise Alfredo Nicosia Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors Molecular Therapy: Oncology MT: Regular Issue cancer vaccine adenovirus vectors herpesvirus vectors immune checkpoint inhibitors neoantigens |
| title | Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors |
| title_full | Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors |
| title_fullStr | Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors |
| title_full_unstemmed | Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors |
| title_short | Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors |
| title_sort | prime and pull of t cell responses against cancer exogenous antigens is effective against cpi resistant tumors |
| topic | MT: Regular Issue cancer vaccine adenovirus vectors herpesvirus vectors immune checkpoint inhibitors neoantigens |
| url | http://www.sciencedirect.com/science/article/pii/S295032992400002X |
| work_keys_str_mv | AT fulviatroise primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT guidoleoni primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT emanuelesasso primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT mariarosariadelsorbo primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT marialuisaesposito primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT giuseppinaromano primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT simonaallocca primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT guendalinafroechlich primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT gabriellacotugno primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT stefaniacapone primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT antonellafolgori primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT elisascarselli primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT annamorenadalise primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors AT alfredonicosia primeandpulloftcellresponsesagainstcancerexogenousantigensiseffectiveagainstcpiresistanttumors |